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Hepatitis C virus (HCV) infection is a curable infection
in the majority of cases, but an effective vaccine remains
elusive. An important explanation for lack of efficacy of
vaccine candidates to protect from HCV may relate to
the dynamic and complex interactions of HCV with host
lipid metabolism. HCV is dependent on interactions with
host lipid metabolism for all stages of the viral life cycle
(Fig. 1)—from attachment and entry into hepatocytes, to
replication and assembly of new viral particles. Produc-
tion of infectious HCV is dependent on the hepatocytes
machinery for export of very low density lipoproteins
(VLDLs).1 HCV replication takes place on lipid droplets
with colocalization of core protein and nonstructural
NS5A to the lipid droplet. Codependency of HCV assem-
bly on VLDL secretion is demonstrated by silencing of
VLDL synthesis components apolipoprotein B (apoB),
apoE, and microsomal triglyceride transfer protein, all of
which inhibit HCV production in Huh 7 cells. Thus, HCV
replication and assembly is dependent on host VLDL
pathways.1
Circulating HCV is associated with lipoproteins as complex
‘‘lipoviral particles’’ (LVPs) (Fig. 2).2 LVPs contain both viral
RNA and viral proteins, and host apolipoprotein constituents
including apoB, apoE, apoA1, and apoC. The structure of
LVP has recently been demonstrated by electron microscopy
studies.2 Low-density LVPs have increased infectivity in cell
culture, compared with high-density viral particles,3 and
decreased susceptibility to antibody mediated neutraliza-
tion.4 Concentrations of LVPs in patients with chronic HCV
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are dynamic and fluctuate with postprandial lipemia.5 LVPs
have been correlated with deranged metabolism including
insulin resistance, altered fasting triglyceride concentrations,
and apoE levels.6 LVPs are detectable in both early acute
and chronic HCV infection, with lower concentrations
observed in early acute HCV infection that subsequently
spontaneously resolved compared with those patients sub-
sequently developing chronic HCV infection.7
Growing evidence suggests that the LVP lipid and apoli-
poprotein components facilitate viral attachment to host
cells by binding to cellular lipoprotein receptors. The ex-
changeable apoE appears to be crucial for infectivity in the
attachment step and masking envelope glycoproteins from
neutralizing antibodies.8 HCV association with lipoproteins
may also be one means by which circulating HCV can
avoid immunoglobulin recognition and evade the host’s
immune surveillance. Given this codependency on host
lipid pathways, any mechanism that would disrupt the LVP
formation would potentially reduce the viral infectivity and
influence outcome after HCV exposure.
Potential resistance to HCV infection has been described
in high-risk injection drug users who do not become HCV-
FIG 1 HCV life cycle. (1) HCV circulates in the blood as LVPs. (2) The LVP leaves the circulation through fenestrated endothelia and
accesses the hepatocytes via the space of Disse. The LVP interacts with host cell receptor molecules such as heparan sulfate glycosamino-
glycan (HS-GAG), low-density lipoprotein receptor (LDLR), and others with high affinity for apolipoproteins. (3) The LVP then binds to
entry factors enabling clathrin-mediated endocytosis. (4) Uncoating of viral capsid delivers viral genomic material to cytoplasmic replica-
tion site. (5) Successful viral entry through lipoprotein channels leads to translation of polypeptides in endoplasmic reticulum. (6) Replica-
tion complex forms 1ssRNA strands via 2ssRNA intermediates in membranous web, which shows characteristics of lipid rafts. (7) Virions
assemble and bud through lipid channels that secrete mature virions via VLDL pathway. (8) Mature virions are released from the cell. LD,
lipid droplet; RER, rough endoplasmic reticulum.
FIG 2 Schematic model of an HCV LVP. HCV circulates in the
blood in association with host lipoproteins in a complex called a LVP
that contains both viral (envelope, core, RNA) and host lipoprotein
constituents including cholesterol, triglycerides, apoB, apoE, and
apoC1.2 LVPs are important in HCV attachment and entry, and may
mask viral epitopes from antibody-mediated neutralization.
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infected despite a long history of likely exposure. These
cases test persistently negative for anti-HCV antibodies
and HCV RNA, and are often referred to as HCV-exposed
uninfected (EU). Many HCV EU cases have demonstrable
HCV-specific T cell responses,9 which serves as further
confirmation of HCV exposure. However, these responses
are typically weak and transient, and it remains unclear
whether they are responsible for any degree of protection
from infection or simply an immunological correlate of
exposure.
Given the importance of lipid pathways for all stages of
the viral life cycle, we have investigated whether variation
in the lipidome of apparently HCV-resistant individuals
may be associated with the EU phenotype.
At the British Association for the Study of the Liver
(BASL) Annual Meeting in Manchester, we reported on a
lipidomics analysis using ultra-performance liquid chroma-
tography mass spectrometry (UPLC-MS) comparing lipid
profiles in serum from HCV ‘‘susceptible’’ with HCV ‘‘resis-
tant’’ cases.10 Initial data were presented from an analysis
of nonfasting serum from HCV-susceptible cases who
were all HCV antibody-positive. These data were divided
into three categories: (1) chronic infection (HCV RNA-posi-
tive), (2) sustained viral responders to previous antiviral
treatment (SVRs; HCV RNA-negative), or (3) spontaneous
resolvers (SRs; HCV RNA-negative). The lipidomes of these
groups were compared with HCV-resistant EU cases.
Principal component analysis and orthogonal projec-
tions to latent structures discriminant analysis (OPLS-DA)
were performed on all data and showed that the HCV
EU cohort had very distinctly different lipidomic features
from all the HCV-susceptible groups, including chronic
infection, SVR, and SR, in both positive and negative ion-
ization modes (Fig. 3).
CONCLUSIONS
Lipidomics profiling demonstrated that the
HCV-resistant EU phenotype was clearly distinct from
HCV-susceptible individuals, even those who clear vire-
mia, either spontaneously or after antiviral therapy. The
HCV–lipid interaction is an essential feature of the virus
life cycle with the early formation of LVPs a key step to
establish infection in susceptible individuals. The
FIG 3 Lipidomics. Multivariate analysis using principal component analysis and OPLS-DA for HCV-resistant cases (EU, n 5 38) compared
with HCV-susceptible (HCV antibody-positive, n 5 295), including chronic HCV patients genotypes 1 or 3 (HCV RNA-positive, n 5 159),
SVRs (n 5 100), and SRs (n 5 36). Summary of data presented as poster 15 at the BASL Annual Meeting 2016.10
REVIEW HCV Susceptibility and Lipid Interactions Shawa et al.
19 | CLINICAL LIVER DISEASE, VOL 10, NO 1, JULY 2017 An Official Learning Resource of AASLD
demonstration of clearly distinct lipid profiles in cases
apparently resistant to HCV infection provides further
support that lipid pathways are crucial for early and per-
sistent HCV infection. Detailed lipid class assignment to
identify specific metabolic pathways associated with HCV
resistance is ongoing and will require additional valida-
tion of identified lipid species. Identification of the pre-
cise lipid moieties that distinguish susceptible from
resistant phenotypes will help our understanding of this
key interaction and may help guide future vaccine design
strategies.
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